Nuvation Bio Inc. is a clinical-stage biopharmaceutical company that develops therapeutic candidates primarily for oncology. Its revenue is currently non-existent as it is in the clinical development phase, but future revenue is expected to come from the commercialization of its drug candidates. The main products under development include NUV-422 (CDK inhibitor), NUV-868 (BET inhibitor), NUV-569 (Wee1 kinase inhibitor), NUV-1182 (adenosine receptor inhibitor), and a drug-drug conjugate platform targeting PARP inhibitors. Factors supporting endurance include a focus on innovative oncology treatments and potential partnerships with larger pharmaceutical companies, while risks include the high failure rate of drug development and reliance on external funding.
—
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company that develops therapeutic candidates primarily for oncology. Its revenue is currently non-existent as it is in the clinical development phase, but future revenue is expected to come from the commercialization of its drug candidates. The main products under development include NUV-422 (CDK inhibitor), NUV-868 (BET inhibitor), NUV-569 (Wee1 kinase inhibitor), NUV-1182 (adenosine receptor inhibitor), and a drug-drug conjugate platform targeting PARP inhibitors. Factors supporting endurance include a focus on innovative oncology treatments and potential partnerships with larger pharmaceutical companies, while risks include the high failure rate of drug development and reliance on external funding.
—
Daily adjusted close
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company that develops therapeutic candidates primarily for oncology. Its revenue is currently non-existent as it is in the clinical development phase, but future revenue is expected to come from the commercialization of its drug candidates. The main products under development include NUV-422 (CDK inhibitor), NUV-868 (BET inhibitor), NUV-569 (Wee1 kinase inhibitor), NUV-1182 (adenosine receptor inhibitor), and a drug-drug conjugate platform targeting PARP inhibitors. Factors supporting endurance include a focus on innovative oncology treatments and potential partnerships with larger pharmaceutical companies, while risks include the high failure rate of drug development and reliance on external funding.